Roche's US subsidiary Genentech announces manufacturing expansion in the United States

Basel, 20 August 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY) today announced plans to invest approximately $750 million in a new device fill-finish manufacturing facility at its 75-acre campus in Hillsboro, Oregon. The investment will bring new end-to-end device filling capabilities to the site and expand capacity to support the future pipeline of innovative medicines across Roche and Genentech.

GlobeNewsWire • Aug 20, 2026

Genentech Announces Manufacturing Expansion in Hillsboro, Oregon

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today announced plans to invest approximately $750 million in a new device fill-finish manufacturing facility at its 75-acre campus in Hillsboro, Oregon. The investment will bring new end-to-end device filling capabilities to the site and expand Genentech's capacity to support its future pipeline of innovative medicines. The Hillsboro investment follows the recent topping out of Ge.

Business Wire • Aug 20, 2026

Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Springs, North Carolina, during a topping out ceremony – a construction milestone marking the completion of the manufacturing building's structural framework. The milestone reflects continued on-time progress on Genentech's approximately $2 billion investment in its first-ever East Coast manufacturing facility.

Business Wire • Aug 18, 2026

Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates

Recursion Pharmaceuticals NASDAQ: RXRX is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Taylor said during a BofA Global Research virtual conference.

MarketBeat • Aug 17, 2026

Drugmakers curb Swiss reimbursement applications over US pricing concerns

Drugmakers are holding back applications for health insurance coverage in Switzerland over concerns that lower prices there could affect their U.S. ​business under drug-pricing policies introduced by the Trump administration, a study ‌showed on Thursday.

Reuters • Aug 13, 2026

Roche Is Getting More Benefit Of The Doubt On Improving Execution

Roche Holding AG remains a respectable long-term hold, supported by a deep pipeline, strong execution, and robust financial resources. Q2 results showed 5% revenue growth and better-than-expected operating margin, validating management's focus on R&D efficiency and cost control. Key upcoming clinical readouts in oncology, immunology, and hematology could drive meaningful revenue shifts over the next 12–24 months.

Seeking Alpha • Aug 13, 2026

Roche launches two new cyclospora tests as US outbreak widens

Roche said on Thursday it launched two new tests to detect cyclospora, as U.S. cyclosporiasis ​cases climbed to record levels this year ‌making the foodborne-illness outbreak one of the largest in the country's recent history.

Reuters • Aug 6, 2026

Roche expands cyclospora testing portfolio to support U.S. public health response

Roche has launched two new, real-time PCR tests to detect cyclospora, a diarrhea-causing infection, to help meet diverse needs of laboratories. The new tests expand the Roche cyclospora portfolio, providing laboratories with more flexible choices.

PRNewsWire • Aug 6, 2026

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer

PARIS--(BUSINESS WIRE)--Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche's investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-m.

Business Wire • Aug 4, 2026

Oakmark Global All Cap Strategy Q2 2026 Portfolio Performance

The portfolio's return was 8.05% (net) for the reporting period. Shares of Samsung Electronics rallied on the back of record first-quarter operating profit, driven by strong AI-related demand across its semiconductor business. As the quarter progressed, elevated medical cost trends began to stabilize, easing pressure on managed care earnings.

Seeking Alpha • Jul 29, 2026